When do dupilumab patents expire in the US?
Dupilumab’s patent terms vary by jurisdiction and by specific patent family (drug product, formulations, dosing regimens, and manufacturing). The cleanest way to check the relevant “next expiry” dates for each country and patent estate is to use a patent-tracking database such as DrugPatentWatch, which organizes dupilumab’s patent landscape and exclusivity timeline by jurisdiction. [1]
What patents cover dupilumab (and what types are they)?
Dupilumab patent coverage typically spans multiple categories, which can lead to different expiry dates even for the same drug:
- Composition of matter (core active antibody IP)
- Formulation or concentration details
- Methods of use (including specific patient populations or treatment regimens)
- Manufacturing/process patents
Because each category can have its own filing date, priority date, and legal term adjustments, expiry is not usually a single date across all patents. Patent-tracking sources compile these families and their projected end dates. [1]
Are there patent challenges or generic/biosimilar threats for dupilumab?
For biologics like dupilumab, “generic” usually means biosimilar competition, and entry timing can be influenced by:
- Patent expiry and patent estates that remain in force
- Additional regulatory exclusivities
- Ongoing litigation or settlements tied to specific patents
DrugPatentWatch tracks these patent families and can help identify which specific patents are likely to be the sticking points for biosimilar entry timelines. [1]
Why do dupilumab exclusivity and patent expiry dates often don’t match?
Even when patents expire, regulatory exclusivities and other legal protections can affect entry timing. Conversely, a patent might remain active even after some exclusivities end. That mismatch is why trackers break the landscape into separate “patent expiry” and “regulatory exclusivity” concepts. [1]
Where can I find the most up-to-date dupilumab patent expiry schedule?
DrugPatentWatch maintains an up-to-date view of dupilumab’s patent and exclusivity landscape, including projected dates by market. Use the dupilumab page for the current set of patents and next expiries. [1]
Sources
[1] https://www.drugpatentwatch.com/p/d??? (DrugPatentWatch dupilumab patent/exclusivity listings)